The Institut National D'excellence En Santé Et Services Sociaux Has Issued Positive Recommendation For Biocryst Pharmaceuticals' Orladeyo (Berotralstat) To Be Reimbursed For The Prevention Of Hereditary Angioedema Attacks In Adults And Pediatric Patients
Portfolio Pulse from Benzinga Newsdesk
The Institut National D'excellence En Santé Et Services Sociaux has issued a positive recommendation for BioCryst Pharmaceuticals' Orladeyo (Berotralstat) to be reimbursed for the prevention of hereditary angioedema attacks in adults and pediatric patients.
September 18, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals' Orladeyo has received a positive recommendation for reimbursement. This could potentially increase the accessibility and sales of the drug, positively impacting the company's revenues.
The positive recommendation for reimbursement of Orladeyo by the Institut National D'excellence En Santé Et Services Sociaux could lead to increased sales as the drug becomes more accessible to patients. This could potentially increase BioCryst Pharmaceuticals' revenues, positively impacting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100